Taking the Guesswork out of Drug Development for Chagas Disease: Recent Advances in Computational Protocols and Clinical Collaborations

on

Researchers at the University of Kent developed a computational protocol using ruthenium-based catalysts to modify naphthoquinones, accelerating effective treatments for Chagas disease by fine-tuning compound properties like effectiveness and stability.4

AN2 Therapeutics and DNDi announced a collaboration to advance AN2-502998, an oral CPSF3 inhibitor for chronic Chagas disease, with Phase I startup underway (completion H2 2025) and Phase II planned for 2026.1

DNDi is advancing early-stage pipelines including UW series and Series-5824, aiming for a Phase III trial by 2028, alongside improved benznidazole regimens in Phase III trials like NuestroBen.2

University of Georgia researchers created the first test of cure for Chagas disease, detecting low levels of T. cruzi to confirm treatment success, addressing limitations in current drug trials.5

Sources:

1. https://dndi.org/press-releases/2025/an2-therapeutics-and-dndi-collaborate-on-clinical-development-of-promising-new-oral-compound-to-treat-chronic-chagas-disease/

2. https://dndi.org/news/2026/2025-rd-programmes-in-review-chagas-disease/

4. https://medicalxpress.com/news/2026-04-guesswork-drug-chagas-disease.html

5. https://news.uga.edu/uga-develops-first-test-of-cure-for-chagas/